US Serial No. 09/832,723 Page 2



REMARKS

Entry of the above amendment prior to examination is respectfully requested.

Please substitute the clean copy of the description of Figure 2. Applicants inadvertently referred to Figures 2A and 2B in the originally filed specification. However, they provided only Figure 2. Figure 2 is the correct figure as originally submitted.

The specification has been amended in accordance with C.F.R. 1.821 through 825 to add the Sequence Listing. Applicants enclose with the amendment a CRF copy of the Sequence Listing and a declaration under 37 CFR 1.821.

Attached hereto is a marked-up version of the changes made to the specification by the current amendment. The attached page is captioned "<u>Version With Markings To Show</u>
Changes Made."

If in the opinion of the Examiner a telephone conference would expedite the prosecution of the subject application, the Examiner is encouraged to call the undersigned at (650) 846-7555.


Respectfully submitted,

Date:

Christopher L. Stone Registration No. 35,696

Genencor International, Inc. 925 Page Mill Road Palo Alto, CA 94304-1013 Phone: (650) 846-7555 Facsimile: (650) 845-6504

US Serial No. 09/832,723



VERSION WITH MARKINGS TO SHOW CHANGES MADE

Paragraph beginning at line 27 of page 4 has been amended as follows:

[Figures 2A and 2B are] Figure 2 is a photograph[s] of a gel of PCR amplified DNA fragments after lysis of target bound phage [Figure 2A illustrates] including TNF- α bound phage and [Figure 2B illustrates] IL-6 and IL-8 bound phage.